Now there are 7 ADT/ART opioids in development. To answer you John... yes it is working very well. Did I buy more after the shareholders meeting? Not as much as I would have liked. Nasrat upped the ante from 5 to 7 with the first 3 that are very close to one another in getting approval.
Didn't go sub-penny with 0 products, won't go sub-penny with 10 products either. More due to launch along with Phase 3 starting near term, I'd advise covering soon.